FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104836161> ?p ?o ?g. }

• W2104836161 abstract "Abstract The endogenous reparative capacity of the adult human brain is low, and chronic neurodegenerative disorders of the central nervous system represent one of the greatest areas of unmet clinical need in the developing world. Novel therapeutic strategies to treat them include: (i) growth factor delivery to boost endogenous repair and (ii) replacement cell therapy, including replacing dopaminergic neurons to treat Parkinson's disease (PD). However, these approaches are restricted not only by rapid degradation of growth factors, but also by the limited availability of cells for transplant and the poor survival of implanted cells that lack the necessary stromal support. We therefore hypothesised that provision of a transient artificial stroma for paracrine delivery of pro-survival factors could overcome both of these issues. Using leukaemia inhibitory factor (LIF) - a proneural, reparative cytokine - formulated as target-specific poly(lactic-co-glycolic acid) (PLGA) nano-particles (LIF-nano-stroma), we discovered that attachment of LIF-nano-stroma to freshly isolated fetal dopaminergic cells improved their survival fourfold: furthermore, in vivo, the number of surviving human fetal dopaminergic cells tended to be higher at 3 months after grafting into the striatum of nude rats, compared with controls treated with empty nanoparticles. In addition, we also analysed the effect of a novel nano-stroma incorporating XAV939 (XAV), a potent inhibitor of the developmentally important Wnt-β-catenin signalling pathway, to investigate whether it could also promote the survival and differentiation of human fetal dopaminergic precursors; we found that the numbers of both tyrosine-hydroxylase-positive neurons (a marker of dopaminergic neurons) and total neurons were increased. This is the first demonstration that LIF-nano-stroma and XAV-nano-stroma each have pro-survival effects on human dopaminergic neurons, with potential value for target-specific modulation of neurogenic fate in cell-based therapies for PD" @default.
• W2104836161 created "2016-06-24" @default.
• W2104836161 creator A5003746204 @default.
• W2104836161 creator A5034543981 @default.
• W2104836161 creator A5057769371 @default.
• W2104836161 creator A5063615196 @default.
• W2104836161 creator A5069757510 @default.
• W2104836161 creator A5081072633 @default.
• W2104836161 creator A5084748006 @default.
• W2104836161 creator A5090239515 @default.
• W2104836161 date "2014-01-01" @default.
• W2104836161 modified "2023-10-13" @default.
• W2104836161 title "Modelling of a targeted nanotherapeutic ‘stroma’ to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt–β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson’s disease" @default.
• W2104836161 cites W1541080127 @default.
• W2104836161 cites W1967533184 @default.
• W2104836161 cites W1976027404 @default.
• W2104836161 cites W1984183707 @default.
• W2104836161 cites W1985734511 @default.
• W2104836161 cites W1987569040 @default.
• W2104836161 cites W1988791308 @default.
• W2104836161 cites W1990841278 @default.
• W2104836161 cites W2002691328 @default.
• W2104836161 cites W2005332192 @default.
• W2104836161 cites W2006733352 @default.
• W2104836161 cites W2006847376 @default.
• W2104836161 cites W2010034085 @default.
• W2104836161 cites W2020398834 @default.
• W2104836161 cites W2023942293 @default.
• W2104836161 cites W2030851291 @default.
• W2104836161 cites W2037810763 @default.
• W2104836161 cites W2057257265 @default.
• W2104836161 cites W2063638559 @default.
• W2104836161 cites W2079313068 @default.
• W2104836161 cites W2081347853 @default.
• W2104836161 cites W2105630842 @default.
• W2104836161 cites W2109653609 @default.
• W2104836161 cites W2125500637 @default.
• W2104836161 cites W2131008756 @default.
• W2104836161 cites W2166254889 @default.
• W2104836161 doi "https://doi.org/10.1242/dmm.015859" @default.
• W2104836161 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4174530" @default.
• W2104836161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25085990" @default.
• W2104836161 hasPublicationYear "2014" @default.
• W2104836161 type Work @default.
• W2104836161 sameAs 2104836161 @default.
• W2104836161 citedByCount "14" @default.
• W2104836161 countsByYear W21048361612015 @default.
• W2104836161 countsByYear W21048361612017 @default.
• W2104836161 countsByYear W21048361612018 @default.
• W2104836161 countsByYear W21048361612019 @default.
• W2104836161 countsByYear W21048361612020 @default.
• W2104836161 countsByYear W21048361612023 @default.
• W2104836161 crossrefType "journal-article" @default.
• W2104836161 hasAuthorship W2104836161A5003746204 @default.
• W2104836161 hasAuthorship W2104836161A5034543981 @default.
• W2104836161 hasAuthorship W2104836161A5057769371 @default.
• W2104836161 hasAuthorship W2104836161A5063615196 @default.
• W2104836161 hasAuthorship W2104836161A5069757510 @default.
• W2104836161 hasAuthorship W2104836161A5081072633 @default.
• W2104836161 hasAuthorship W2104836161A5084748006 @default.
• W2104836161 hasAuthorship W2104836161A5090239515 @default.
• W2104836161 hasBestOaLocation W21048361611 @default.
• W2104836161 hasConcept C126322002 @default.
• W2104836161 hasConcept C134018914 @default.
• W2104836161 hasConcept C137183658 @default.
• W2104836161 hasConcept C137620995 @default.
• W2104836161 hasConcept C159167319 @default.
• W2104836161 hasConcept C16930146 @default.
• W2104836161 hasConcept C170493617 @default.
• W2104836161 hasConcept C203014093 @default.
• W2104836161 hasConcept C204232928 @default.
• W2104836161 hasConcept C2778690821 @default.
• W2104836161 hasConcept C502942594 @default.
• W2104836161 hasConcept C513476851 @default.
• W2104836161 hasConcept C52124034 @default.
• W2104836161 hasConcept C62478195 @default.
• W2104836161 hasConcept C71924100 @default.
• W2104836161 hasConcept C7876069 @default.
• W2104836161 hasConcept C86803240 @default.
• W2104836161 hasConcept C95444343 @default.
• W2104836161 hasConceptScore W2104836161C126322002 @default.
• W2104836161 hasConceptScore W2104836161C134018914 @default.
• W2104836161 hasConceptScore W2104836161C137183658 @default.
• W2104836161 hasConceptScore W2104836161C137620995 @default.
• W2104836161 hasConceptScore W2104836161C159167319 @default.
• W2104836161 hasConceptScore W2104836161C16930146 @default.
• W2104836161 hasConceptScore W2104836161C170493617 @default.
• W2104836161 hasConceptScore W2104836161C203014093 @default.
• W2104836161 hasConceptScore W2104836161C204232928 @default.
• W2104836161 hasConceptScore W2104836161C2778690821 @default.
• W2104836161 hasConceptScore W2104836161C502942594 @default.
• W2104836161 hasConceptScore W2104836161C513476851 @default.
• W2104836161 hasConceptScore W2104836161C52124034 @default.
• W2104836161 hasConceptScore W2104836161C62478195 @default.
• W2104836161 hasConceptScore W2104836161C71924100 @default.
• W2104836161 hasConceptScore W2104836161C7876069 @default.
• W2104836161 hasConceptScore W2104836161C86803240 @default.
• W2104836161 hasConceptScore W2104836161C95444343 @default.
• W2104836161 hasLocation W21048361611 @default.
• W2104836161 hasLocation W21048361612 @default.

• next